louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04832074: Immediate Stiffness Changes in Myofascial Trigger Points After Dry Needling
Official title: Immediate Stiffness Changes in Upper Trapezius Active Myofascial Trigger Points After Dry Needling in Patients With Neck Pain: A Randomized, Double-Blinded, Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myofascial Pain Syndrome
Neck Pain
Trigger Point Pain, Myofascial
Lead sponsor: Camilo Jose Cela University
Sponsor class: OTHER
First posted: 2021-04-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, Double-Blinded, Placebo-Controlled Trial
Primary purpose: TREATMENT

Brief summary: Shear-wave elastography (SWE) is considered as a useful tool for quantifying muscle stiffness. Considering that Myofascial Trigger Points (MTrP) are defined as "hyperirritable zones in contracted bands of muscle, thought to be caused by muscle overload or stress" and the effectiveness of dry needling applied to active MTrP for reducing pain and disability, the aim of this study is to assess the effects of sham and real dry needling, applied to active MTrP in the upper trapezius muscle in patients with chronic neck pain, on the muscle stiffness in two areas: 1) the most symptomatic area and 2) a control point.


Eligibility criteria: Inclusion Criteria:

* Patients between 18 and 65 and
* Presence of mechanical neck pain for at least three months duration
* Presence of at least one active MTrP in the Upper Trapezius muscle

Exclusion Criteria:

* Neck pain of traumatic origin (such as whiplash-associated disorder)
* Current use of any kind of analgesic therapy
* Presenting any condition usually considered a perpetuating factor of MTrPs, such as fibromyalgia, hypothyroidism, or iron deficiencies
* Presenting any contraindication for Dry Needling application
* Neuropathies (e.g., radiculopathy)
* Bilateral Pain

Primary outcomes:
measure: SWE - Young modulus
timeFrame: Baseline
measure: SWE - Young modulus
timeFrame: 10 minutes
measure: SWE - Local shear wave speed
timeFrame: Baseline
measure: SWE - Local shear wave speed
timeFrame: 10 minutes
measure: Pain Pressure Thresholds
timeFrame: Baseline
measure: Pain Pressure Thresholds
timeFrame: 10 minutes
Secondary outcomes:
measure: Visual Analogue Scale
timeFrame: Baseline
measure: Neck Disability Index
timeFrame: Baseline
Other outcomes:
Locations:
city: Pozuelo De Alarcón
country: Spain
facility: Francisco de Vitoria University
state: Madrid
Study officials:
affiliation: Camilo José Cela University
name: Juan Antonio Valera-Calero, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Valera-Calero JA, Sanchez-Jorge S, Buffet-Garcia J, Varol U, Fernandez-de-Las-Penas C, Alvarez-Gonzalez J. Changes in stiffness at active myofascial trigger points of the upper trapezius after dry needling in patients with chronic neck pain: a randomized controlled trial. Acupunct Med. 2023 Jun;41(3):121-129. doi: 10.1177/09645284221104831. Epub 2022 Jun 28.
Clinical trial NCT01533974: PATH Partnering to Achieve Tobacco-free Health
Official title: Acceptance & Commitment Therapy for Smoking Cessation (Aka PATH Study - Partnering to Achieve Tobacco-free Health)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Smoking Cessation
Lead sponsor: Fred Hutchinson Cancer Center
Sponsor class: OTHER
Collaborators: name: Kaiser Permanente
First posted: 2012-02-16
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The overall aim of this 5-year project is to capitalize on the strong theoretical and promising empirical evidence for Acceptance \& Commitment Therapy (ACT) as an intervention for smoking cessation by comparing the effectiveness of ACT against standard cognitive behavioral therapy (CBT) counseling when both are offered with nicotine replacement therapy (NRT) and delivered within a real world healthcare setting.


Eligibility criteria: Inclusion Criteria:

1. aged 18 and older;
2. smoke at least 10 cigarettes per day for every day in the past month;
3. want to quit smoking in the next 30 days;
4. are able to speak and read in English;
5. are a GH member enrolled living in the greater Seattle area;
6. are not currently participating in other smoking cessation interventions;
7. not currently using other nicotine products (e.g., smokeless tobacco)
8. are willing to attend five 90-minute group intervention sessions and to receive NRT over the next 3 months;
9. have no medical contraindications for NRT use (i.e., pregnant, breastfeeding, recent heart attack, or skin allergy preventing use of the patch, as assessed using the standard GH contraindication screening for NRT patch);
10. no household member currently enrolled in the study

Exclusion Criteria:

1. fails to meet the eligibility criteria above;
2. has a significant cognitive or physical impairment (e.g., dementia, deafness) that would preclude full participation in the counseling sessions. This will be assessed both by self-report and by in-person assessment at the baseline enrollment appointment

Primary outcomes:
measure: Number of Participants Who Stopped Smoking by 12 Month Post Treatment
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Group Health Cooperative
state: Washington
Study officials:
affiliation: Fred Hutchinson Cancer Center
name: Jonathan Bricker
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jackson S, Brown J, Norris E, Livingstone-Banks J, Hayes E, Lindson N. Mindfulness for smoking cessation. Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD013696. doi: 10.1002/14651858.CD013696.pub2.
Clinical trial NCT01684774: Comparison Between Ultrasound-guided and Landmark-guided Ankle Blocks
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Analgesia
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-09-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult ASA I-III (American Society of Anesthesiologists classification) patients undergoing orthopedic foot operation with osteotomy

Brief summary: The investigators will be comparing ultrasound-guided (USG) ankle block and anatomic landmark-guided (ALG) ankle block to determine which of these procedures is better in surgical anesthesia and in postoperative pain relief.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing orthopedic foot operation with osteotomy

Exclusion Criteria:

* Skin infection near block injection site
* Allergy to local anesthetics
* Coagulopathy with INR \>1.4.
* Dementia

Primary outcomes:
measure: Surgical Anesthesia Sufficient
timeFrame: Thirty minutes
measure: Post-operative Pain Relief
timeFrame: Twenty-four hours
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT02191774: Medical Abortion up to 10 Weeks Gestation at Home
Official title: Medical Abortion up to 10 Weeks Gestation at Home
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy Complications
Legally Induced Abortion Without Mention of Complication
Keywords: Medical abortion
Home abortion
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2014-07-16
Enrollment: 273
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with an unwanted pregnancy opting for medical abortion

Brief summary: Medical abortion performed in the womens home has shown to be safe and acceptable up to 9 weeks of gestation. Our project is aiming to confirm our hypothesis that it is equally effective, safe and acceptable when the gestation is more advanced, up to 10 weeks of gestation.

Detailed description: The study will include 600 women opting for medical abortion. Women wanting to perform the last part of the abortion in their homes will be invited to participate. 300 women with a pregnancy up to 9 weeks of gestation (63 days) will be compared to 300 women with a gestation length between 64 and 70 days of gestation. The primary endpoints will be number of patients with an incomplete abortion, with a need for surgical or pharmaceutical intervention.

Secondary endpoints include duration of bleeding, acceptance and satisfaction with the method and number of additional visits to the clinic/facility.

The study will be performed in five abortion clinics in Sweden.

Eligibility criteria: Inclusion Criteria:

* Healthy
* Requesting and eligible for medical abortion
* Confirmed intrauterine pregnancy
* Gestational length no more than 70 days
* Hemoglobin over 100g/l

Exclusion Criteria:

* Anemia
* Contraindication to mifepristone (steroid-dependant cancer, porphyria)
* Breast feeding
* Advanced pregnancy (\>70 days)
* Known liver disease
* Bleeding disorder
* Arterial hypertension

Primary outcomes:
measure: Number of incomplete abortions
timeFrame: 4 weeks after treatment
Secondary outcomes:
measure: Duration of bleeding
timeFrame: 4 weeks after treatment
measure: Acceptance and satisfaction of treatment
timeFrame: 4 weeks after treatment
measure: Number of additional visits to the clinic
timeFrame: 4 weeks after treatment
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Södersjukhuset
Study officials:
affiliation: Karolinska Institutet
name: Lena Marions, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05060874: Gripwise® Versus JAMAR®
Official title: Comparison of Gripstrength Assessment Between the Gripwise® and JAMAR® Dynamometers in Elderly Inpatients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Age-Related Sarcopenia
Keywords: aged
inpatients
hand strength
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2021-09-29
Enrollment: 348
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: aged inpatients hospitalized in CAEN University Hospital

Brief summary: It is recommended to screen ageing patients for sarcopenia, due to the increased risk of morbimortality if detected positive. According to the consensus of the European Working Group on Sarcopenia in Older People, the diagnosis of sarcopenia is based, among other things, on grip strength measurement.

Our study will compare the performance of the new GRIPWISE digital device with the mechanical dynamometer JAMAR, the gold standard currently used to assess the grip strength. We propose to evaluate it in an elderly hospitalized population where the prevalence of sarcopenia is likely to be high due to the high prevalence of various chronic illness, notably oncological and cardiological ones.

This cross-sectional study will include 348 patients.


Eligibility criteria: Inclusion Criteria:

* men and women aged 65 or over
* affiliated to a health insurance
* Francophone.

Exclusion Criteria:

* - refusal to participate
* unable to communicate
* unable to use both hands (dominant and non-dominant)

Primary outcomes:
measure: Comparison between Jamar® and Gripwise® values for grip strength measurement
timeFrame: day1
Secondary outcomes:
measure: comparison according to the patient's position
timeFrame: day1
measure: number of attempt to reach the maximum value
timeFrame: day1
measure: factors influencing detected weakness
timeFrame: day1
measure: satisfaction using the devices
timeFrame: day1
Other outcomes:
Locations:
city: Caen
country: France
facility: Caen University Hospital
Study officials:
affiliation: Caen UH
name: Bérengère Beauplet, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02035774: A Novel Selective Block of the Suprascapular Nerve
Official title: A Novel Selective Block of the Suprascapular Nerve
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Ligament Injury
Fracture
Keywords: Brachial plexus block
Suprascapular nerve block
Lead sponsor: University Hospital of North Norway
Sponsor class: OTHER
Collaborators: name: University of Tromso
First posted: 2014-01-14
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients who receive the lateral and sagittal infraclavicular block (LSIB) tend to supinate their hand and forearm which may hamper optimal positioning for surgery of the dorsal side of the hand. The investigators think that this supination is caused by lateral rotation in the shoulder. The main lateral rotator of the shoulder is the infraspinatus muscle, which is innervated by the suprascapular nerve (SSN).The investigators hypothesized that optimal positioning of the hand for surgery on the dorsal side of the hand may be achieved by performing a SSN block (SSNB) in addition to the LSIB.

Detailed description: According to the hypothesis the investigators will perform a double blind , placebo controlled study to answer the research question above.

Eligibility criteria: Inclusion Criteria:

* Patients with American Society of Anesthesiologists physical status (ASA) I- III
* age between 18 and 70 years
* body mass index between 20 and 36 kg/m2 scheduled for elective hand surgery.

Exclusion Criteria:

We will measure the angle between wrist and horizontal plane while the patient is supine and the extended arm 75° abducted.

* Patient who are not able to pronate the hand ≤15° before block performance, will be excluded from the study.
* Patients will also be excluded if they are pregnant, have contraindications to regional anesthesia, coagulation disorder, allergy to local anesthetics (LA), atrioventricular block, peripheral neuropathy or drug-treated diabetes.
* Patients using other anticoagulation drugs than acetylsalicylic acids or dipyridamol will be excluded.

Primary outcomes:
measure: Wrist angle
timeFrame: 30 minutes
Secondary outcomes:
measure: Satisfaction score
timeFrame: 3 hours
Other outcomes:
Locations:
city: Tromsø
country: Norway
facility: University Hospital of North Norway
state: Troms
Study officials:
affiliation: University Hospital of North Norway
name: Lars M Ytrebø, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hackworth RJ. A new and simplified approach to target the suprascapular nerve with ultrasound. J Clin Anesth. 2013 Jun;25(4):347-8. doi: 10.1016/j.jclinane.2013.01.006. Epub 2013 May 1. No abstract available.
citation: Siegenthaler A, Moriggl B, Mlekusch S, Schliessbach J, Haug M, Curatolo M, Eichenberger U. Ultrasound-guided suprascapular nerve block, description of a novel supraclavicular approach. Reg Anesth Pain Med. 2012 May-Jun;37(3):325-8. doi: 10.1097/AAP.0b013e3182409168.
Clinical trial NCT01745874: Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging
Official title: Diagnostic Value of Whole-Body MRI Compared to FDG-PET-CT for Rectal Cancer Preoperative Staging, Before and After Neoadjuvant Treatment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rectal Cancer
Keywords: Rectal cancer
Whole-body MRI
FDG-PET-CT
preoperative staging
Lead sponsor: University of Lausanne Hospitals
Sponsor class: OTHER
First posted: 2012-12-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with a rectal cancer

Brief summary: The purpose of this study is to determine whether whole-body MRI (WB-MRI) accuracy is superior to FDG-PET-CT considered as the gold-standard for the staging of distant lesions of rectal cancer.

Detailed description: Rectal cancer is the second cause of mortality after lung cancer in industrialized countries and represent 28% of colorectal carcinomas. Despite major improvements in diagnosis and treatment made those last years,mortality and morbidity remains high, because of high prevalence of metastasis and local recurrence. A accurate initial staging is of paramount importance for an appropriate treatment (neoadjuvant chemiotherapy and radiotherapy, surgery).

Actually, there is no international consensus concerning imaging for the staging of rectal cancer and modalities used are variable from one center to another.

WB-MRI represented a attractive and promising technique for the staging of rectal cancer, free of ionizing radiation .

Eligibility criteria: Inclusion Criteria:

* rectal cancer T3 N+ or T3 or T4

Exclusion Criteria:

* renal failure
* allergy to iodinated contrast medium
* contraindication to MRI

Primary outcomes:
measure: Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment
timeFrame: baseline and 1 week before surgery
Secondary outcomes:
measure: Tumoral regression after neoadjuvant treatment
timeFrame: baseline and six weeks after the end of the neoadjuvant treatment
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: University of Lausanne Hospitals
state: Vaud
Study officials:
affiliation: University of Lausanne Hospitals
name: Milena Cerny
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Lausanne Hospitals
name: Sabine Schmidt Kobbe, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00895674: Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Official title: Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Renal Cell
Carcinoma, Renal Cell (Advanced)
Keywords: Advanced Renal Cell Carcinoma
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-05-08
Enrollment: 2840
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a diagnosis of advanced RCC

Brief summary: Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.


Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Sorafenib

Exclusion Criteria:

* Exclusion criteria must be read in conjunction with the local product information

Primary outcomes:
measure: Tumor status
timeFrame: After about 3, 6, 9 and 12 months
Secondary outcomes:
measure: Treatment duration
timeFrame: At end of study after about 12 months
measure: Safety of sorafenib treatment
timeFrame: At every documented visit for about 12 months
measure: Progression-free survival
timeFrame: Calculation at end of study after about 12 months
measure: Status of Metastases
timeFrame: After about 3, 6, 9 and 12 months
measure: Performance status (ECOG)
timeFrame: After about 3, 6, 9 and 12 months
Other outcomes:
Locations:
city: Many Locations
country: Argentina
city: Many Locations
country: Austria
city: Many Locations
country: China
city: Many Locations
country: Colombia
city: Many Locations
country: Czech Republic
city: Many Locations
country: France
city: Many Locations
country: Germany
city: Many Locations
country: Greece
city: Many Locations
country: Indonesia
city: Many Locations
country: Korea, Republic of
city: Many Locations
country: Mexico
city: Many Locations
country: Netherlands
city: Many Locations
country: Philippines
city: Many Locations
country: Poland
city: Many Locations
country: Russian Federation
city: Many Locations
country: Slovakia
city: Many Locations
country: Slovenia
city: Many Locations
country: Sweden
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02274974: Post-Caesarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine
Official title: Post-Caesarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine;Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain, Postoperative
Keywords: incisional
infiltration
cs
lidocaine
epinephrine
Adverse Reaction to Topical or Infiltrative Lidocaine
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
First posted: 2014-10-27
Enrollment: 160
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Study to compare between efficacy of post-caesarean section infiltration with lidocaine and epinephrine versus lidocaine only to reduce post-incisional pain.

Detailed description: assessment of adding of epinephrine to lidocaine as local infiltrator to post-caesarean section wound in prolongation of its anaesthetic effect.

Eligibility criteria: Inclusion Criteria:

* Women undergoing caesarean delivery under General anesthesia for various indications.
* Women refuse spinal anesthesia.

Exclusion Criteria:

* Known or suspected sensitivity to local anesthesia.
* Medical disorders induced by pregnancy (Pre-eclamptic toxemia, gestational diabetes mellitus, Hepatic diseases, homeostatic disorder)
* Medical disorders aggravated by pregnancy (cardiovascular disease, pulmonary disease, renal disease, neurological disease, metabolic or infectious diseases).
* Women who hemo-dynamically unstable.
* Lack of adequate verbal communication.

Primary outcomes:
measure: Timing of first analgesic request.
timeFrame: 24 hours
Secondary outcomes:
measure: Duration of cesarean section
timeFrame: 30 min to 90 min
measure: Onset of breast breastfeeding
timeFrame: 24 hours
measure: Onset of mobilization
timeFrame: 24 hours
measure: Duration of hospital stay
timeFrame: 24 hours to 48 hours
measure: Side effects of local infiltration of lidocaine and epinephrine
timeFrame: 7 days
measure: Postoperative pyrexia
timeFrame: 24 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Post-Caesarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine;
Study officials:
affiliation: Ain Shams Maternity Hospital(AinShamsMH)
name: Amr H Yhia, M.D, MRCOG
role: PRINCIPAL_INVESTIGATOR
References:
citation: AbdElRhman G Ali,cairo,egypt,Post-Caerarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine.